Haptoglobin-targeted therapies could offer a dual benefit in malignancies: one in reducing the oxidative stress associated with haemolysis in cancer patients and the other in mitigating the immunosuppressive effects of haptoglobin that facilitate tumour growth. This evidence concerns the gene HP and neoplasm.